Dr. Cokey Nguyen was appointed President and Chief Executive Officer and named to the Board of Directors in September 2024. Dr. Nguyen is a leader in the fields of cell therapy and oncology with significant experience in research and development of cell therapies as well as oncology drug discovery and development in biotech. Dr. Nguyen joined Atara in May 2021 as Chief Scientific Officer, where he focused on leading the development of next-generation allogeneic cell therapies for cancer and autoimmune diseases. With his passion for delivering transformative therapies to patients, Dr. Nguyen helped advance Atara’s existing programs and further expanded the pipeline through pioneering science, teamwork, and a commitment to excellence.
Prior to joining Atara, Dr. Nguyen was at Fate Therapeutics, where, as Vice President, Innovation, Research and Development, he directed strategy for discovery and innovation efforts, and spearheaded the corporate collaboration program with ONO Pharma. Prior to that, he was leader of the targeted immunotherapy group on the Oncology R&D team at Pfizer, producing bispecific antibodies for solid tumors and hematological malignancies and bringing them into the clinic.
Dr. Nguyen’s bench science experience includes work in tumor metabolism, gene expression and molecular biology. He holds numerous patents for iPSC and immune effector cells and has been published in various peer-reviewed journals. Dr. Nguyen has also been active in successful business development activities, including, while at Janssen, evaluating Legend’s BCMA-directed CAR T program and supporting the Janssen/Legend partnership.
Dr. Nguyen received his undergraduate degree in biology from Harvard College and a Ph.D. in Immunology from Washington University in St. Louis. He was a Postdoctoral Associate at the Center for Cancer Research at the Massachusetts Institute of Technology (MIT), where he focused on the identification and characterization of BRCT domains as novel phosphor-binding domains in DNA damage pathways.
In his free time, Cokey is an avid reader, is a fan of motorsports and enjoys cycling.
What is Anhco Nguyen's net worth?
The estimated net worth of Anhco Nguyen is at least $1.27 million as of August 17th, 2026. Dr. Nguyen owns 132,775 shares of Atara Biotherapeutics stock worth more than $1,270,657 as of September 14th. This net worth approximation does not reflect any other investments that Dr. Nguyen may own. Learn More about Anhco Nguyen's net worth.
How do I contact Anhco Nguyen?
Has Anhco Nguyen been buying or selling shares of Atara Biotherapeutics?
Within the last three months, Anhco Nguyen has sold $40,900.96 in shares of Atara Biotherapeutics stock. Most recently, Anhco Nguyen sold 5,062 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $8.08, for a transaction totalling $40,900.96. Following the completion of the sale, the chief executive officer now directly owns 132,775 shares of the company's stock, valued at $1,072,822. Learn More on Anhco Nguyen's trading history.
Who are Atara Biotherapeutics' active insiders?
Are insiders buying or selling shares of Atara Biotherapeutics?
During the last year, Atara Biotherapeutics insiders bought shares 1 times. They purchased a total of 104,166 shares worth more than $999,993.60. During the last year, insiders at the biotechnology company sold shares 8 times. They sold a total of 413,240 shares worth more than $3,851,596.86. The most recent insider tranaction occured on September, 4th when Director Brian N Cherry bought 104,166 shares worth more than $999,993.60. Insiders at Atara Biotherapeutics own 41.2% of the company.
Learn More about insider trades at Atara Biotherapeutics. Information on this page was last updated on 9/4/2026.
